MTOR and neoplasm: Previous studies have demonstrated that the inhibition of the PI3K/AKT/mTOR pathway can reduce the numbers of MDSCs and Tregs and decrease their secretion of immunosuppressive factors, such as TGF-β and IL-10, thereby improving immune activity within the tumor microenvironment [52, 53].